Navigation Links
PUR Biologics’ Novel Orthopedic Developments Supported by Two New US Patents
Date:9/10/2013

Irvine, CA (PRWEB) September 10, 2013

PUR Biologics, LLC, a joint venture focused on the emerging field of biologics for musculoskeletal conditions, including spine, dental and medical device applications, today announced that the United States Patent & Trademark Office has issued two patents covering the multipotent stem cell-derived material utilized by PUR, and its applications in the repair and regeneration of tissue.

The US Patent & Trademark Office issued patent 8,524,494, entitled “Low Oxygen Tension and bFGF Generates a Multipotent Stem Cell from a Fibroblast In Vitro”, and patent 8,530,415, entitled “Repair and/or Regeneration of Cells with a Composition Produced by Culturing Fibroblast Cells under Hypoxic Conditions”, to PUR’s joint venture partner, Histogen, Inc., on September 3 and September 9, 2013, respectively.

The issued patents cover Histogen’s novel technology which triggers the de-differentiation of fibroblast cells into multipotent stem cells through low oxygen and special culture conditions, as well as methods of inducing tissue repair and regeneration by contacting cells with the naturally-secreted multipotent cell conditioned media (CCM) and extracellular matrix (ECM) materials.

“These novel multipotent cell-derived materials hold tremendous potential in orthopedic applications, where we seek to regenerate musculoskeletal tissues and support stem cell growth,” said Ryan Fernan, CEO of PUR Biologics. “Particularly exciting to us is the ability of the material to induce angiogenesis, which is not addressed with currently available orthopedic products.”

Unlike other stem cell-derived therapies, Histogen’s process uniquely begins with newborn fibroblast cells, a safe, well-established and non-controversial cell source, and converts the cells into multipotent stem cells without genetic manipulation. PUR Biologics is currently researching and developing products based upon the CCM and ECM materials produced by these multipotent cells, which have potential benefit in a number of orthopedic applications such as bone and cartilage regeneration.

“While there is a lot of excitement and promise around stem cell-derived treatments in orthopedics, therapies utilizing embryonic stem cells or genetically-manipulated induced pluripotent stem cells carry inherent ethical and potential safety concerns for patients,” said Dr. Burak Ozgur, Chief of Neurosurgery Spine Service at Hoag Hospital. “Products that could capture the benefits of stem cell treatments without these concerns, such as the multipotent cell materials being developed by PUR, hold tremendous potential as the future of orthopedics.”

About PUR Biologics
PUR Biologics is dedicated to providing regenerative biologic solutions to address musculoskeletal surgical needs, including spine, dental, ligament and medical device coating applications. In addition to distribution of approved allograft and biologic products, PUR is focused on development of next-generation orthopedic products based upon human protein and growth factor materials for bone and tissue regeneration. For more information visit http://www.purbiologics.com.

About Histogen
Histogen is a regenerative medicine company developing solutions based upon the products of cells grown under proprietary conditions that mimic the embryonic environment, including low oxygen and suspension. Through this unique technology process, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen's technology focuses on stimulating a patient's own stem cells by delivering a proprietary complex of multipotent human proteins that have been shown to support stem cell growth and differentiation. For more information, please visit http://www.histogen.com.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11106113.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Study Published in Nature Biotechnology Demonstrates Ability of Modernas Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue
2. Novel topological crystalline insulator shows mass appeal
3. Novelda Appoints Alf-Egil Bogen as Chief Executive Officer to Lead the Company to the Next Level
4. Medasense Receives Patent Approval for Novel Pain-Monitoring System
5. Micropharma Limited announces new agreement to commercialize novel natural health products
6. Pure Transplant Solutions Launches Crowdfunding Campaign for Its Novel Technology Poised to Change the Future of Organ Transplantation
7. Further Evidence that the PhotoActivation of PRP (PAPRP) is a Novel and Effective Treatment for Osteoarthritis and Knee Pain
8. Novel study using new technologies outlines importance of California condor social groups
9. Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies
10. NuView Life Sciences Announces Presentation of Data for Novel Prostate and Bladder Cancer Molecular Diagnostic at SNMMI
11. Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing”
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Florida , February 11, 2016 ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), a ... announced today that its Thermomedics subsidiary, which markets ... on its growth plan in January 2016, including ... distributors, increasing sequential monthly sales growth, and establishing ...
(Date:2/10/2016)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a ... Mitsui & Co. Ltd., its partner in the ... investing an additional CDN$25 million in the joint venture ... 30% to 40%.  Mitsui will also play a stronger ... Sarnia , providing dedicated resources alongside ...
(Date:2/10/2016)... (PRWEB) , ... February 10, ... ... REGN) today announced that it has joined the Human Vaccines Project, a ... infectious diseases and cancer. , The Human Vaccines Project brings together ...
(Date:2/10/2016)... ... February 10, 2016 , ... HOLLOWAY AMERICA, a ... Engineering (ISPE) Rocky Mountain Chapter 21st Annual Vendor Exhibition on Thursday, February 18, ... 100 tables for its annual event, which will run from 3:00 p.m. - ...
Breaking Biology Technology:
(Date:2/1/2016)... February 1, 2016 Rising sales ... drive global touchfree intuitive gesture control market ... Rising sales of consumer electronics coupled with new technological ... size through 2020   ... with new technological advancements to drive global touchfree intuitive ...
(Date:1/28/2016)... SAN JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: ... financial results for its second quarter ended December 31, 2015. ... the second quarter of fiscal 2016 increased 2 percent compared to ... the second quarter of fiscal 2016 was $35.0 million, or $0.93 ... Non-GAAP net income for the first quarter of fiscal 2016 ...
(Date:1/25/2016)... -- Glencoe Software, the world-leading supplier of image data management ... the data management solution OMERO Plus for the newly ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... Phenotypic analysis measures the characteristics and behavior of cells, ... such as health and disease, the presence or absence ...
Breaking Biology News(10 mins):